Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

134.42 +0.49 (+0.37%)
Streaming Delayed Price Updated: 2:20 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
Via Benzinga
HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, In Expert Review
Via Benzinga
Which COVID-19 Vaccine(s) Significantly Prevented Deaths - Read To Find Out
Via Benzinga
AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)
Via Benzinga
AstraZeneca's Combination Inhaler Shines In Phase 3 Asthma Trial
Via Benzinga
Drugmakers, Health Authorities Discarding Several Million COVID-19 Vaccine Doses: Report
Via Benzinga
AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters
Via Benzinga
AstraZeneca Strengthens Its Hematological Cancer Pipeline With TeneoTwo Acquisition
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire< 
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
Via Benzinga
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine
Via Benzinga
AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
Via Benzinga
AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder
Via Benzinga
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
Via Benzinga
Why Mereo BioPharma Shares Are Jumping Today
Via Benzinga
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
Via Benzinga
European Regulator Approves AstraZeneca's COVID-19 shot As Booster
Via Benzinga
Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco
Via Benzinga
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV). 
Via Benzinga
FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Goes Under Priority FDA Review For Bile Duct Cancer
Via Benzinga
AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook
Via Benzinga
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer
Via Benzinga
AstraZeneca's Tremelimumab/Imfinzi Combo Regime Goes Under Priority FDA Review For Liver Cancer
Via Benzinga
World's Largest Vaccine Manufacturer Stops Making COVID-19 Vaccines As 200M Doses Pile-Up: Bloomberg
Serum Institute of India Ltd, the world’s largest vaccine manufacturer, has stopped making new batches of COVID-19 shots after its stockpile grew to 200 million doses amid a global supply glut, 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.